MSP Recovery, Inc.
MSP Recovery, Inc. (MSPRW) Stock Competitors & Peer Comparison
See (MSPRW) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Healthcare Information Services Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| MSPRW | $0.07 | +3150.00% | 7K | N/A | N/A | N/A |
| VEEV | $281.35 | -1.00% | 45.9B | 59.56 | $4.72 | N/A |
| GEHC | $69.85 | -2.06% | 31.9B | 14.31 | $4.88 | +0.19% |
| GEHCV | $56.00 | -4.08% | 25.5B | N/A | N/A | +0.19% |
| DOCS | $57.33 | -2.42% | 10.7B | 51.62 | $1.11 | N/A |
| SGFY | $30.49 | +0.07% | 8.9B | 70.91 | $0.43 | N/A |
| HQY | $91.06 | -6.12% | 7.9B | 66.47 | $1.37 | N/A |
| RCM | $14.31 | N/A | 6B | -102.21 | -$0.14 | N/A |
| BTSGU | $70.16 | -3.05% | 3.6B | N/A | N/A | N/A |
| BTSG | $19.64 | -4.89% | 3.5B | 72.74 | $0.27 | N/A |
Stock Comparison
MSPRW vs VEEV Comparison August 2025
MSPRW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPRW stands at 7K. In comparison, VEEV has a market cap of 45.9B. Regarding current trading prices, MSPRW is priced at $0.07, while VEEV trades at $281.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPRW currently has a P/E ratio of N/A, whereas VEEV's P/E ratio is 59.56. In terms of profitability, MSPRW's ROE is -3.08%, compared to VEEV's ROE of +0.14%. Regarding short-term risk, MSPRW is less volatile compared to VEEV. This indicates potentially lower risk in terms of short-term price fluctuations for MSPRW.Check VEEV's competition here
MSPRW vs GEHC Comparison August 2025
MSPRW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPRW stands at 7K. In comparison, GEHC has a market cap of 31.9B. Regarding current trading prices, MSPRW is priced at $0.07, while GEHC trades at $69.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPRW currently has a P/E ratio of N/A, whereas GEHC's P/E ratio is 14.31. In terms of profitability, MSPRW's ROE is -3.08%, compared to GEHC's ROE of +0.25%. Regarding short-term risk, MSPRW is less volatile compared to GEHC. This indicates potentially lower risk in terms of short-term price fluctuations for MSPRW.Check GEHC's competition here
MSPRW vs GEHCV Comparison August 2025
MSPRW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPRW stands at 7K. In comparison, GEHCV has a market cap of 25.5B. Regarding current trading prices, MSPRW is priced at $0.07, while GEHCV trades at $56.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPRW currently has a P/E ratio of N/A, whereas GEHCV's P/E ratio is N/A. In terms of profitability, MSPRW's ROE is -3.08%, compared to GEHCV's ROE of +0.25%. Regarding short-term risk, MSPRW is less volatile compared to GEHCV. This indicates potentially lower risk in terms of short-term price fluctuations for MSPRW.Check GEHCV's competition here
MSPRW vs DOCS Comparison August 2025
MSPRW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPRW stands at 7K. In comparison, DOCS has a market cap of 10.7B. Regarding current trading prices, MSPRW is priced at $0.07, while DOCS trades at $57.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPRW currently has a P/E ratio of N/A, whereas DOCS's P/E ratio is 51.62. In terms of profitability, MSPRW's ROE is -3.08%, compared to DOCS's ROE of +0.22%. Regarding short-term risk, MSPRW is less volatile compared to DOCS. This indicates potentially lower risk in terms of short-term price fluctuations for MSPRW.Check DOCS's competition here
MSPRW vs SGFY Comparison August 2025
MSPRW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPRW stands at 7K. In comparison, SGFY has a market cap of 8.9B. Regarding current trading prices, MSPRW is priced at $0.07, while SGFY trades at $30.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPRW currently has a P/E ratio of N/A, whereas SGFY's P/E ratio is 70.91. In terms of profitability, MSPRW's ROE is -3.08%, compared to SGFY's ROE of -0.15%. Regarding short-term risk, MSPRW is less volatile compared to SGFY. This indicates potentially lower risk in terms of short-term price fluctuations for MSPRW.Check SGFY's competition here
MSPRW vs HQY Comparison August 2025
MSPRW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPRW stands at 7K. In comparison, HQY has a market cap of 7.9B. Regarding current trading prices, MSPRW is priced at $0.07, while HQY trades at $91.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPRW currently has a P/E ratio of N/A, whereas HQY's P/E ratio is 66.47. In terms of profitability, MSPRW's ROE is -3.08%, compared to HQY's ROE of +0.06%. Regarding short-term risk, MSPRW is less volatile compared to HQY. This indicates potentially lower risk in terms of short-term price fluctuations for MSPRW.Check HQY's competition here
MSPRW vs RCM Comparison August 2025
MSPRW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPRW stands at 7K. In comparison, RCM has a market cap of 6B. Regarding current trading prices, MSPRW is priced at $0.07, while RCM trades at $14.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPRW currently has a P/E ratio of N/A, whereas RCM's P/E ratio is -102.21. In terms of profitability, MSPRW's ROE is -3.08%, compared to RCM's ROE of -0.02%. Regarding short-term risk, MSPRW and RCM have similar daily volatility (0.00).Check RCM's competition here
MSPRW vs BTSGU Comparison August 2025
MSPRW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPRW stands at 7K. In comparison, BTSGU has a market cap of 3.6B. Regarding current trading prices, MSPRW is priced at $0.07, while BTSGU trades at $70.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPRW currently has a P/E ratio of N/A, whereas BTSGU's P/E ratio is N/A. In terms of profitability, MSPRW's ROE is -3.08%, compared to BTSGU's ROE of +0.04%. Regarding short-term risk, MSPRW is less volatile compared to BTSGU. This indicates potentially lower risk in terms of short-term price fluctuations for MSPRW.Check BTSGU's competition here
MSPRW vs BTSG Comparison August 2025
MSPRW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPRW stands at 7K. In comparison, BTSG has a market cap of 3.5B. Regarding current trading prices, MSPRW is priced at $0.07, while BTSG trades at $19.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPRW currently has a P/E ratio of N/A, whereas BTSG's P/E ratio is 72.74. In terms of profitability, MSPRW's ROE is -3.08%, compared to BTSG's ROE of +0.04%. Regarding short-term risk, MSPRW is less volatile compared to BTSG. This indicates potentially lower risk in terms of short-term price fluctuations for MSPRW.Check BTSG's competition here
MSPRW vs ONEM Comparison August 2025
MSPRW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPRW stands at 7K. In comparison, ONEM has a market cap of 3.4B. Regarding current trading prices, MSPRW is priced at $0.07, while ONEM trades at $16.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPRW currently has a P/E ratio of N/A, whereas ONEM's P/E ratio is -7.77. In terms of profitability, MSPRW's ROE is -3.08%, compared to ONEM's ROE of -0.24%. Regarding short-term risk, MSPRW is less volatile compared to ONEM. This indicates potentially lower risk in terms of short-term price fluctuations for MSPRW.Check ONEM's competition here
MSPRW vs WGS Comparison August 2025
MSPRW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPRW stands at 7K. In comparison, WGS has a market cap of 2.9B. Regarding current trading prices, MSPRW is priced at $0.07, while WGS trades at $101.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPRW currently has a P/E ratio of N/A, whereas WGS's P/E ratio is 1270.00. In terms of profitability, MSPRW's ROE is -3.08%, compared to WGS's ROE of +0.01%. Regarding short-term risk, MSPRW is less volatile compared to WGS. This indicates potentially lower risk in terms of short-term price fluctuations for MSPRW.Check WGS's competition here
MSPRW vs PRVA Comparison August 2025
MSPRW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPRW stands at 7K. In comparison, PRVA has a market cap of 2.3B. Regarding current trading prices, MSPRW is priced at $0.07, while PRVA trades at $18.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPRW currently has a P/E ratio of N/A, whereas PRVA's P/E ratio is 157.17. In terms of profitability, MSPRW's ROE is -3.08%, compared to PRVA's ROE of +0.02%. Regarding short-term risk, MSPRW is less volatile compared to PRVA. This indicates potentially lower risk in terms of short-term price fluctuations for MSPRW.Check PRVA's competition here
MSPRW vs PGNY Comparison August 2025
MSPRW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPRW stands at 7K. In comparison, PGNY has a market cap of 1.9B. Regarding current trading prices, MSPRW is priced at $0.07, while PGNY trades at $22.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPRW currently has a P/E ratio of N/A, whereas PGNY's P/E ratio is 39.46. In terms of profitability, MSPRW's ROE is -3.08%, compared to PGNY's ROE of +0.12%. Regarding short-term risk, MSPRW is less volatile compared to PGNY. This indicates potentially lower risk in terms of short-term price fluctuations for MSPRW.Check PGNY's competition here
MSPRW vs PINC Comparison August 2025
MSPRW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPRW stands at 7K. In comparison, PINC has a market cap of 1.8B. Regarding current trading prices, MSPRW is priced at $0.07, while PINC trades at $21.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPRW currently has a P/E ratio of N/A, whereas PINC's P/E ratio is 20.85. In terms of profitability, MSPRW's ROE is -3.08%, compared to PINC's ROE of +0.03%. Regarding short-term risk, MSPRW is less volatile compared to PINC. This indicates potentially lower risk in terms of short-term price fluctuations for MSPRW.Check PINC's competition here
MSPRW vs TXG Comparison August 2025
MSPRW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPRW stands at 7K. In comparison, TXG has a market cap of 1.6B. Regarding current trading prices, MSPRW is priced at $0.07, while TXG trades at $13.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPRW currently has a P/E ratio of N/A, whereas TXG's P/E ratio is -10.06. In terms of profitability, MSPRW's ROE is -3.08%, compared to TXG's ROE of -0.22%. Regarding short-term risk, MSPRW is less volatile compared to TXG. This indicates potentially lower risk in terms of short-term price fluctuations for MSPRW.Check TXG's competition here
MSPRW vs GDRX Comparison August 2025
MSPRW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPRW stands at 7K. In comparison, GDRX has a market cap of 1.6B. Regarding current trading prices, MSPRW is priced at $0.07, while GDRX trades at $4.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPRW currently has a P/E ratio of N/A, whereas GDRX's P/E ratio is 64.71. In terms of profitability, MSPRW's ROE is -3.08%, compared to GDRX's ROE of +0.07%. Regarding short-term risk, MSPRW is less volatile compared to GDRX. This indicates potentially lower risk in terms of short-term price fluctuations for MSPRW.Check GDRX's competition here
MSPRW vs NXGN Comparison August 2025
MSPRW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPRW stands at 7K. In comparison, NXGN has a market cap of 1.6B. Regarding current trading prices, MSPRW is priced at $0.07, while NXGN trades at $23.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPRW currently has a P/E ratio of N/A, whereas NXGN's P/E ratio is -266.00. In terms of profitability, MSPRW's ROE is -3.08%, compared to NXGN's ROE of -0.01%. Regarding short-term risk, MSPRW is less volatile compared to NXGN. This indicates potentially lower risk in terms of short-term price fluctuations for MSPRW.Check NXGN's competition here
MSPRW vs PHR Comparison August 2025
MSPRW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPRW stands at 7K. In comparison, PHR has a market cap of 1.6B. Regarding current trading prices, MSPRW is priced at $0.07, while PHR trades at $26.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPRW currently has a P/E ratio of N/A, whereas PHR's P/E ratio is -35.58. In terms of profitability, MSPRW's ROE is -3.08%, compared to PHR's ROE of -0.16%. Regarding short-term risk, MSPRW is less volatile compared to PHR. This indicates potentially lower risk in terms of short-term price fluctuations for MSPRW.Check PHR's competition here
MSPRW vs CERT Comparison August 2025
MSPRW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPRW stands at 7K. In comparison, CERT has a market cap of 1.5B. Regarding current trading prices, MSPRW is priced at $0.07, while CERT trades at $9.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPRW currently has a P/E ratio of N/A, whereas CERT's P/E ratio is -477.00. In terms of profitability, MSPRW's ROE is -3.08%, compared to CERT's ROE of -0.00%. Regarding short-term risk, MSPRW is less volatile compared to CERT. This indicates potentially lower risk in terms of short-term price fluctuations for MSPRW.Check CERT's competition here
MSPRW vs SDGR Comparison August 2025
MSPRW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPRW stands at 7K. In comparison, SDGR has a market cap of 1.4B. Regarding current trading prices, MSPRW is priced at $0.07, while SDGR trades at $19.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPRW currently has a P/E ratio of N/A, whereas SDGR's P/E ratio is -7.43. In terms of profitability, MSPRW's ROE is -3.08%, compared to SDGR's ROE of -0.45%. Regarding short-term risk, MSPRW is less volatile compared to SDGR. This indicates potentially lower risk in terms of short-term price fluctuations for MSPRW.Check SDGR's competition here
MSPRW vs OMCL Comparison August 2025
MSPRW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPRW stands at 7K. In comparison, OMCL has a market cap of 1.4B. Regarding current trading prices, MSPRW is priced at $0.07, while OMCL trades at $29.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPRW currently has a P/E ratio of N/A, whereas OMCL's P/E ratio is 64.70. In terms of profitability, MSPRW's ROE is -3.08%, compared to OMCL's ROE of +0.02%. Regarding short-term risk, MSPRW is less volatile compared to OMCL. This indicates potentially lower risk in terms of short-term price fluctuations for MSPRW.Check OMCL's competition here
MSPRW vs AGTI Comparison August 2025
MSPRW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPRW stands at 7K. In comparison, AGTI has a market cap of 1.4B. Regarding current trading prices, MSPRW is priced at $0.07, while AGTI trades at $10.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPRW currently has a P/E ratio of N/A, whereas AGTI's P/E ratio is -71.79. In terms of profitability, MSPRW's ROE is -3.08%, compared to AGTI's ROE of -0.01%. Regarding short-term risk, MSPRW is less volatile compared to AGTI. This indicates potentially lower risk in terms of short-term price fluctuations for MSPRW.Check AGTI's competition here
MSPRW vs TDOC Comparison August 2025
MSPRW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPRW stands at 7K. In comparison, TDOC has a market cap of 1.2B. Regarding current trading prices, MSPRW is priced at $0.07, while TDOC trades at $6.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPRW currently has a P/E ratio of N/A, whereas TDOC's P/E ratio is -6.03. In terms of profitability, MSPRW's ROE is -3.08%, compared to TDOC's ROE of -0.14%. Regarding short-term risk, MSPRW is less volatile compared to TDOC. This indicates potentially lower risk in terms of short-term price fluctuations for MSPRW.Check TDOC's competition here
MSPRW vs EVH Comparison August 2025
MSPRW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPRW stands at 7K. In comparison, EVH has a market cap of 1.2B. Regarding current trading prices, MSPRW is priced at $0.07, while EVH trades at $9.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPRW currently has a P/E ratio of N/A, whereas EVH's P/E ratio is -8.18. In terms of profitability, MSPRW's ROE is -3.08%, compared to EVH's ROE of -0.11%. Regarding short-term risk, MSPRW is less volatile compared to EVH. This indicates potentially lower risk in terms of short-term price fluctuations for MSPRW.Check EVH's competition here
MSPRW vs HSTM Comparison August 2025
MSPRW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPRW stands at 7K. In comparison, HSTM has a market cap of 782.2M. Regarding current trading prices, MSPRW is priced at $0.07, while HSTM trades at $25.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPRW currently has a P/E ratio of N/A, whereas HSTM's P/E ratio is 40.68. In terms of profitability, MSPRW's ROE is -3.08%, compared to HSTM's ROE of +0.05%. Regarding short-term risk, MSPRW is less volatile compared to HSTM. This indicates potentially lower risk in terms of short-term price fluctuations for MSPRW.Check HSTM's competition here
MSPRW vs CTEV Comparison August 2025
MSPRW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPRW stands at 7K. In comparison, CTEV has a market cap of 632.7M. Regarding current trading prices, MSPRW is priced at $0.07, while CTEV trades at $38.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPRW currently has a P/E ratio of N/A, whereas CTEV's P/E ratio is -0.53. In terms of profitability, MSPRW's ROE is -3.08%, compared to CTEV's ROE of -5.18%. Regarding short-term risk, MSPRW is less volatile compared to CTEV. This indicates potentially lower risk in terms of short-term price fluctuations for MSPRW.Check CTEV's competition here
MSPRW vs MPLN-WT Comparison August 2025
MSPRW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPRW stands at 7K. In comparison, MPLN-WT has a market cap of 625.2M. Regarding current trading prices, MSPRW is priced at $0.07, while MPLN-WT trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPRW currently has a P/E ratio of N/A, whereas MPLN-WT's P/E ratio is N/A. In terms of profitability, MSPRW's ROE is -3.08%, compared to MPLN-WT's ROE of -5.18%. Regarding short-term risk, MSPRW is less volatile compared to MPLN-WT. This indicates potentially lower risk in terms of short-term price fluctuations for MSPRW.Check MPLN-WT's competition here
MSPRW vs ACCD Comparison August 2025
MSPRW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPRW stands at 7K. In comparison, ACCD has a market cap of 575.6M. Regarding current trading prices, MSPRW is priced at $0.07, while ACCD trades at $7.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPRW currently has a P/E ratio of N/A, whereas ACCD's P/E ratio is -3.08. In terms of profitability, MSPRW's ROE is -3.08%, compared to ACCD's ROE of -0.45%. Regarding short-term risk, MSPRW and ACCD have similar daily volatility (0.00).Check ACCD's competition here
MSPRW vs SY Comparison August 2025
MSPRW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPRW stands at 7K. In comparison, SY has a market cap of 562.8M. Regarding current trading prices, MSPRW is priced at $0.07, while SY trades at $4.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPRW currently has a P/E ratio of N/A, whereas SY's P/E ratio is -5.33. In terms of profitability, MSPRW's ROE is -3.08%, compared to SY's ROE of -0.28%. Regarding short-term risk, MSPRW is less volatile compared to SY. This indicates potentially lower risk in terms of short-term price fluctuations for MSPRW.Check SY's competition here
MSPRW vs SHCR Comparison August 2025
MSPRW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPRW stands at 7K. In comparison, SHCR has a market cap of 531.8M. Regarding current trading prices, MSPRW is priced at $0.07, while SHCR trades at $1.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPRW currently has a P/E ratio of N/A, whereas SHCR's P/E ratio is -3.76. In terms of profitability, MSPRW's ROE is -3.08%, compared to SHCR's ROE of -0.24%. Regarding short-term risk, MSPRW is less volatile compared to SHCR. This indicates potentially lower risk in terms of short-term price fluctuations for MSPRW.Check SHCR's competition here
MSPRW vs NUTX Comparison August 2025
MSPRW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPRW stands at 7K. In comparison, NUTX has a market cap of 466.6M. Regarding current trading prices, MSPRW is priced at $0.07, while NUTX trades at $84.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPRW currently has a P/E ratio of N/A, whereas NUTX's P/E ratio is 6.80. In terms of profitability, MSPRW's ROE is -3.08%, compared to NUTX's ROE of +0.71%. Regarding short-term risk, MSPRW is less volatile compared to NUTX. This indicates potentially lower risk in terms of short-term price fluctuations for MSPRW.Check NUTX's competition here
MSPRW vs DH Comparison August 2025
MSPRW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPRW stands at 7K. In comparison, DH has a market cap of 401.5M. Regarding current trading prices, MSPRW is priced at $0.07, while DH trades at $3.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPRW currently has a P/E ratio of N/A, whereas DH's P/E ratio is -0.85. In terms of profitability, MSPRW's ROE is -3.08%, compared to DH's ROE of -1.07%. Regarding short-term risk, MSPRW is less volatile compared to DH. This indicates potentially lower risk in terms of short-term price fluctuations for MSPRW.Check DH's competition here
MSPRW vs SLGCW Comparison August 2025
MSPRW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPRW stands at 7K. In comparison, SLGCW has a market cap of 396.2M. Regarding current trading prices, MSPRW is priced at $0.07, while SLGCW trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPRW currently has a P/E ratio of N/A, whereas SLGCW's P/E ratio is -0.16. In terms of profitability, MSPRW's ROE is -3.08%, compared to SLGCW's ROE of -0.19%. Regarding short-term risk, MSPRW is less volatile compared to SLGCW. This indicates potentially lower risk in terms of short-term price fluctuations for MSPRW.Check SLGCW's competition here
MSPRW vs SLGC Comparison August 2025
MSPRW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPRW stands at 7K. In comparison, SLGC has a market cap of 396.2M. Regarding current trading prices, MSPRW is priced at $0.07, while SLGC trades at $2.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPRW currently has a P/E ratio of N/A, whereas SLGC's P/E ratio is -3.04. In terms of profitability, MSPRW's ROE is -3.08%, compared to SLGC's ROE of -0.19%. Regarding short-term risk, MSPRW is less volatile compared to SLGC. This indicates potentially lower risk in terms of short-term price fluctuations for MSPRW.Check SLGC's competition here
MSPRW vs SPOK Comparison August 2025
MSPRW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPRW stands at 7K. In comparison, SPOK has a market cap of 380.8M. Regarding current trading prices, MSPRW is priced at $0.07, while SPOK trades at $18.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPRW currently has a P/E ratio of N/A, whereas SPOK's P/E ratio is 22.30. In terms of profitability, MSPRW's ROE is -3.08%, compared to SPOK's ROE of +0.15%. Regarding short-term risk, MSPRW is less volatile compared to SPOK. This indicates potentially lower risk in terms of short-term price fluctuations for MSPRW.Check SPOK's competition here
MSPRW vs MPLN Comparison August 2025
MSPRW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPRW stands at 7K. In comparison, MPLN has a market cap of 375M. Regarding current trading prices, MSPRW is priced at $0.07, while MPLN trades at $23.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPRW currently has a P/E ratio of N/A, whereas MPLN's P/E ratio is -0.23. In terms of profitability, MSPRW's ROE is -3.08%, compared to MPLN's ROE of -5.18%. Regarding short-term risk, MSPRW is less volatile compared to MPLN. This indicates potentially lower risk in terms of short-term price fluctuations for MSPRW.Check MPLN's competition here
MSPRW vs TBRG Comparison August 2025
MSPRW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPRW stands at 7K. In comparison, TBRG has a market cap of 308.6M. Regarding current trading prices, MSPRW is priced at $0.07, while TBRG trades at $20.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPRW currently has a P/E ratio of N/A, whereas TBRG's P/E ratio is -16.84. In terms of profitability, MSPRW's ROE is -3.08%, compared to TBRG's ROE of -0.10%. Regarding short-term risk, MSPRW is less volatile compared to TBRG. This indicates potentially lower risk in terms of short-term price fluctuations for MSPRW.Check TBRG's competition here
MSPRW vs NRC Comparison August 2025
MSPRW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPRW stands at 7K. In comparison, NRC has a market cap of 286.6M. Regarding current trading prices, MSPRW is priced at $0.07, while NRC trades at $12.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPRW currently has a P/E ratio of N/A, whereas NRC's P/E ratio is 16.34. In terms of profitability, MSPRW's ROE is -3.08%, compared to NRC's ROE of +0.61%. Regarding short-term risk, MSPRW is less volatile compared to NRC. This indicates potentially lower risk in terms of short-term price fluctuations for MSPRW.Check NRC's competition here
MSPRW vs TRHC Comparison August 2025
MSPRW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPRW stands at 7K. In comparison, TRHC has a market cap of 284M. Regarding current trading prices, MSPRW is priced at $0.07, while TRHC trades at $10.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPRW currently has a P/E ratio of N/A, whereas TRHC's P/E ratio is -4.27. In terms of profitability, MSPRW's ROE is -3.08%, compared to TRHC's ROE of +121.31%. Regarding short-term risk, MSPRW is less volatile compared to TRHC. This indicates potentially lower risk in terms of short-term price fluctuations for MSPRW.Check TRHC's competition here
MSPRW vs SLP Comparison August 2025
MSPRW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPRW stands at 7K. In comparison, SLP has a market cap of 257.6M. Regarding current trading prices, MSPRW is priced at $0.07, while SLP trades at $12.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPRW currently has a P/E ratio of N/A, whereas SLP's P/E ratio is -4.06. In terms of profitability, MSPRW's ROE is -3.08%, compared to SLP's ROE of -0.37%. Regarding short-term risk, MSPRW is less volatile compared to SLP. This indicates potentially lower risk in terms of short-term price fluctuations for MSPRW.Check SLP's competition here
MSPRW vs SMFR Comparison August 2025
MSPRW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPRW stands at 7K. In comparison, SMFR has a market cap of 246.4M. Regarding current trading prices, MSPRW is priced at $0.07, while SMFR trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPRW currently has a P/E ratio of N/A, whereas SMFR's P/E ratio is N/A. In terms of profitability, MSPRW's ROE is -3.08%, compared to SMFR's ROE of +0.01%. Regarding short-term risk, MSPRW is less volatile compared to SMFR. This indicates potentially lower risk in terms of short-term price fluctuations for MSPRW.Check SMFR's competition here
MSPRW vs HCAT Comparison August 2025
MSPRW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPRW stands at 7K. In comparison, HCAT has a market cap of 245M. Regarding current trading prices, MSPRW is priced at $0.07, while HCAT trades at $3.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPRW currently has a P/E ratio of N/A, whereas HCAT's P/E ratio is -3.06. In terms of profitability, MSPRW's ROE is -3.08%, compared to HCAT's ROE of -0.20%. Regarding short-term risk, MSPRW is less volatile compared to HCAT. This indicates potentially lower risk in terms of short-term price fluctuations for MSPRW.Check HCAT's competition here
MSPRW vs OPRX Comparison August 2025
MSPRW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPRW stands at 7K. In comparison, OPRX has a market cap of 231.2M. Regarding current trading prices, MSPRW is priced at $0.07, while OPRX trades at $12.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPRW currently has a P/E ratio of N/A, whereas OPRX's P/E ratio is -14.88. In terms of profitability, MSPRW's ROE is -3.08%, compared to OPRX's ROE of -0.13%. Regarding short-term risk, MSPRW is less volatile compared to OPRX. This indicates potentially lower risk in terms of short-term price fluctuations for MSPRW.Check OPRX's competition here
MSPRW vs SOPH Comparison August 2025
MSPRW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPRW stands at 7K. In comparison, SOPH has a market cap of 211.2M. Regarding current trading prices, MSPRW is priced at $0.07, while SOPH trades at $3.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPRW currently has a P/E ratio of N/A, whereas SOPH's P/E ratio is -3.16. In terms of profitability, MSPRW's ROE is -3.08%, compared to SOPH's ROE of -0.63%. Regarding short-term risk, MSPRW is less volatile compared to SOPH. This indicates potentially lower risk in terms of short-term price fluctuations for MSPRW.Check SOPH's competition here
MSPRW vs CPSI Comparison August 2025
MSPRW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPRW stands at 7K. In comparison, CPSI has a market cap of 133.7M. Regarding current trading prices, MSPRW is priced at $0.07, while CPSI trades at $9.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPRW currently has a P/E ratio of N/A, whereas CPSI's P/E ratio is -183.80. In terms of profitability, MSPRW's ROE is -3.08%, compared to CPSI's ROE of -0.18%. Regarding short-term risk, MSPRW is less volatile compared to CPSI. This indicates potentially lower risk in terms of short-term price fluctuations for MSPRW.Check CPSI's competition here
MSPRW vs EUDA Comparison August 2025
MSPRW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPRW stands at 7K. In comparison, EUDA has a market cap of 119.6M. Regarding current trading prices, MSPRW is priced at $0.07, while EUDA trades at $3.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPRW currently has a P/E ratio of N/A, whereas EUDA's P/E ratio is -5.96. In terms of profitability, MSPRW's ROE is -3.08%, compared to EUDA's ROE of +3.05%. Regarding short-term risk, MSPRW is less volatile compared to EUDA. This indicates potentially lower risk in terms of short-term price fluctuations for MSPRW.Check EUDA's competition here
MSPRW vs AUGX Comparison August 2025
MSPRW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPRW stands at 7K. In comparison, AUGX has a market cap of 115.9M. Regarding current trading prices, MSPRW is priced at $0.07, while AUGX trades at $2.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPRW currently has a P/E ratio of N/A, whereas AUGX's P/E ratio is -4.99. In terms of profitability, MSPRW's ROE is -3.08%, compared to AUGX's ROE of -1.13%. Regarding short-term risk, MSPRW is less volatile compared to AUGX. This indicates potentially lower risk in terms of short-term price fluctuations for MSPRW.Check AUGX's competition here
MSPRW vs AMWL Comparison August 2025
MSPRW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPRW stands at 7K. In comparison, AMWL has a market cap of 109.6M. Regarding current trading prices, MSPRW is priced at $0.07, while AMWL trades at $7.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPRW currently has a P/E ratio of N/A, whereas AMWL's P/E ratio is -0.68. In terms of profitability, MSPRW's ROE is -3.08%, compared to AMWL's ROE of -0.48%. Regarding short-term risk, MSPRW is less volatile compared to AMWL. This indicates potentially lower risk in terms of short-term price fluctuations for MSPRW.Check AMWL's competition here
MSPRW vs CCLDO Comparison August 2025
MSPRW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPRW stands at 7K. In comparison, CCLDO has a market cap of 102.1M. Regarding current trading prices, MSPRW is priced at $0.07, while CCLDO trades at $20.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPRW currently has a P/E ratio of N/A, whereas CCLDO's P/E ratio is N/A. In terms of profitability, MSPRW's ROE is -3.08%, compared to CCLDO's ROE of +0.21%. Regarding short-term risk, MSPRW is less volatile compared to CCLDO. This indicates potentially lower risk in terms of short-term price fluctuations for MSPRW.Check CCLDO's competition here
MSPRW vs CCLD Comparison August 2025
MSPRW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPRW stands at 7K. In comparison, CCLD has a market cap of 97.8M. Regarding current trading prices, MSPRW is priced at $0.07, while CCLD trades at $2.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPRW currently has a P/E ratio of N/A, whereas CCLD's P/E ratio is -10.50. In terms of profitability, MSPRW's ROE is -3.08%, compared to CCLD's ROE of +0.21%. Regarding short-term risk, MSPRW is less volatile compared to CCLD. This indicates potentially lower risk in terms of short-term price fluctuations for MSPRW.Check CCLD's competition here
MSPRW vs FORA Comparison August 2025
MSPRW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPRW stands at 7K. In comparison, FORA has a market cap of 60.2M. Regarding current trading prices, MSPRW is priced at $0.07, while FORA trades at $1.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPRW currently has a P/E ratio of N/A, whereas FORA's P/E ratio is -16.08. In terms of profitability, MSPRW's ROE is -3.08%, compared to FORA's ROE of -0.13%. Regarding short-term risk, MSPRW is less volatile compared to FORA. This indicates potentially lower risk in terms of short-term price fluctuations for MSPRW.Check FORA's competition here
MSPRW vs CCLDP Comparison August 2025
MSPRW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPRW stands at 7K. In comparison, CCLDP has a market cap of 59.9M. Regarding current trading prices, MSPRW is priced at $0.07, while CCLDP trades at $19.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPRW currently has a P/E ratio of N/A, whereas CCLDP's P/E ratio is N/A. In terms of profitability, MSPRW's ROE is -3.08%, compared to CCLDP's ROE of +0.21%. Regarding short-term risk, MSPRW and CCLDP have similar daily volatility (0.00).Check CCLDP's competition here
MSPRW vs SNCE Comparison August 2025
MSPRW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPRW stands at 7K. In comparison, SNCE has a market cap of 34.7M. Regarding current trading prices, MSPRW is priced at $0.07, while SNCE trades at $5.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPRW currently has a P/E ratio of N/A, whereas SNCE's P/E ratio is -0.27. In terms of profitability, MSPRW's ROE is -3.08%, compared to SNCE's ROE of -0.47%. Regarding short-term risk, MSPRW is less volatile compared to SNCE. This indicates potentially lower risk in terms of short-term price fluctuations for MSPRW.Check SNCE's competition here
MSPRW vs BEAT Comparison August 2025
MSPRW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPRW stands at 7K. In comparison, BEAT has a market cap of 34.5M. Regarding current trading prices, MSPRW is priced at $0.07, while BEAT trades at $1.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPRW currently has a P/E ratio of N/A, whereas BEAT's P/E ratio is -1.38. In terms of profitability, MSPRW's ROE is -3.08%, compared to BEAT's ROE of -3.58%. Regarding short-term risk, MSPRW is less volatile compared to BEAT. This indicates potentially lower risk in terms of short-term price fluctuations for MSPRW.Check BEAT's competition here
MSPRW vs AKLI Comparison August 2025
MSPRW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPRW stands at 7K. In comparison, AKLI has a market cap of 34.1M. Regarding current trading prices, MSPRW is priced at $0.07, while AKLI trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPRW currently has a P/E ratio of N/A, whereas AKLI's P/E ratio is -0.71. In terms of profitability, MSPRW's ROE is -3.08%, compared to AKLI's ROE of -0.38%. Regarding short-term risk, MSPRW is less volatile compared to AKLI. This indicates potentially lower risk in terms of short-term price fluctuations for MSPRW.Check AKLI's competition here
MSPRW vs SHLT Comparison August 2025
MSPRW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPRW stands at 7K. In comparison, SHLT has a market cap of 33.6M. Regarding current trading prices, MSPRW is priced at $0.07, while SHLT trades at $2.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPRW currently has a P/E ratio of N/A, whereas SHLT's P/E ratio is -3.87. In terms of profitability, MSPRW's ROE is -3.08%, compared to SHLT's ROE of -0.07%. Regarding short-term risk, MSPRW and SHLT have similar daily volatility (0.00).Check SHLT's competition here
MSPRW vs SHCRW Comparison August 2025
MSPRW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPRW stands at 7K. In comparison, SHCRW has a market cap of 32.5M. Regarding current trading prices, MSPRW is priced at $0.07, while SHCRW trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPRW currently has a P/E ratio of N/A, whereas SHCRW's P/E ratio is -0.00. In terms of profitability, MSPRW's ROE is -3.08%, compared to SHCRW's ROE of -0.24%. Regarding short-term risk, MSPRW is less volatile compared to SHCRW. This indicates potentially lower risk in terms of short-term price fluctuations for MSPRW.Check SHCRW's competition here
MSPRW vs BEATW Comparison August 2025
MSPRW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPRW stands at 7K. In comparison, BEATW has a market cap of 26M. Regarding current trading prices, MSPRW is priced at $0.07, while BEATW trades at $0.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPRW currently has a P/E ratio of N/A, whereas BEATW's P/E ratio is -0.49. In terms of profitability, MSPRW's ROE is -3.08%, compared to BEATW's ROE of -3.58%. Regarding short-term risk, MSPRW is less volatile compared to BEATW. This indicates potentially lower risk in terms of short-term price fluctuations for MSPRW.Check BEATW's competition here
MSPRW vs SCNX Comparison August 2025
MSPRW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPRW stands at 7K. In comparison, SCNX has a market cap of 25.1M. Regarding current trading prices, MSPRW is priced at $0.07, while SCNX trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPRW currently has a P/E ratio of N/A, whereas SCNX's P/E ratio is 2.89. In terms of profitability, MSPRW's ROE is -3.08%, compared to SCNX's ROE of -0.24%. Regarding short-term risk, MSPRW is less volatile compared to SCNX. This indicates potentially lower risk in terms of short-term price fluctuations for MSPRW.Check SCNX's competition here
MSPRW vs STRM Comparison August 2025
MSPRW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPRW stands at 7K. In comparison, STRM has a market cap of 23.1M. Regarding current trading prices, MSPRW is priced at $0.07, while STRM trades at $5.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPRW currently has a P/E ratio of N/A, whereas STRM's P/E ratio is -2.39. In terms of profitability, MSPRW's ROE is -3.08%, compared to STRM's ROE of -0.68%. Regarding short-term risk, MSPRW is less volatile compared to STRM. This indicates potentially lower risk in terms of short-term price fluctuations for MSPRW.Check STRM's competition here
MSPRW vs RNLX Comparison August 2025
MSPRW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPRW stands at 7K. In comparison, RNLX has a market cap of 22.5M. Regarding current trading prices, MSPRW is priced at $0.07, while RNLX trades at $0.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPRW currently has a P/E ratio of N/A, whereas RNLX's P/E ratio is -0.33. In terms of profitability, MSPRW's ROE is -3.08%, compared to RNLX's ROE of +1.94%. Regarding short-term risk, MSPRW is less volatile compared to RNLX. This indicates potentially lower risk in terms of short-term price fluctuations for MSPRW.Check RNLX's competition here
MSPRW vs LIFW Comparison August 2025
MSPRW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPRW stands at 7K. In comparison, LIFW has a market cap of 22.4M. Regarding current trading prices, MSPRW is priced at $0.07, while LIFW trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPRW currently has a P/E ratio of N/A, whereas LIFW's P/E ratio is -0.02. In terms of profitability, MSPRW's ROE is -3.08%, compared to LIFW's ROE of -3.08%. Regarding short-term risk, MSPRW and LIFW have similar daily volatility (0.00).Check LIFW's competition here
MSPRW vs VSEEW Comparison August 2025
MSPRW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPRW stands at 7K. In comparison, VSEEW has a market cap of 20.1M. Regarding current trading prices, MSPRW is priced at $0.07, while VSEEW trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPRW currently has a P/E ratio of N/A, whereas VSEEW's P/E ratio is N/A. In terms of profitability, MSPRW's ROE is -3.08%, compared to VSEEW's ROE of -6.10%. Regarding short-term risk, MSPRW is less volatile compared to VSEEW. This indicates potentially lower risk in terms of short-term price fluctuations for MSPRW.Check VSEEW's competition here
MSPRW vs VSEE Comparison August 2025
MSPRW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPRW stands at 7K. In comparison, VSEE has a market cap of 19.2M. Regarding current trading prices, MSPRW is priced at $0.07, while VSEE trades at $1.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPRW currently has a P/E ratio of N/A, whereas VSEE's P/E ratio is -12.25. In terms of profitability, MSPRW's ROE is -3.08%, compared to VSEE's ROE of -6.10%. Regarding short-term risk, MSPRW is less volatile compared to VSEE. This indicates potentially lower risk in terms of short-term price fluctuations for MSPRW.Check VSEE's competition here
MSPRW vs MGRX Comparison August 2025
MSPRW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPRW stands at 7K. In comparison, MGRX has a market cap of 18.2M. Regarding current trading prices, MSPRW is priced at $0.07, while MGRX trades at $1.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPRW currently has a P/E ratio of N/A, whereas MGRX's P/E ratio is -0.37. In terms of profitability, MSPRW's ROE is -3.08%, compared to MGRX's ROE of -0.73%. Regarding short-term risk, MSPRW is less volatile compared to MGRX. This indicates potentially lower risk in terms of short-term price fluctuations for MSPRW.Check MGRX's competition here
MSPRW vs ONMD Comparison August 2025
MSPRW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPRW stands at 7K. In comparison, ONMD has a market cap of 14.4M. Regarding current trading prices, MSPRW is priced at $0.07, while ONMD trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPRW currently has a P/E ratio of N/A, whereas ONMD's P/E ratio is -1.34. In terms of profitability, MSPRW's ROE is -3.08%, compared to ONMD's ROE of +0.60%. Regarding short-term risk, MSPRW is less volatile compared to ONMD. This indicates potentially lower risk in terms of short-term price fluctuations for MSPRW.Check ONMD's competition here
MSPRW vs BBLN Comparison August 2025
MSPRW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPRW stands at 7K. In comparison, BBLN has a market cap of 14.1M. Regarding current trading prices, MSPRW is priced at $0.07, while BBLN trades at $0.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPRW currently has a P/E ratio of N/A, whereas BBLN's P/E ratio is -0.04. In terms of profitability, MSPRW's ROE is -3.08%, compared to BBLN's ROE of +4.89%. Regarding short-term risk, MSPRW is less volatile compared to BBLN. This indicates potentially lower risk in terms of short-term price fluctuations for MSPRW.Check BBLN's competition here
MSPRW vs INOV Comparison August 2025
MSPRW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPRW stands at 7K. In comparison, INOV has a market cap of 12.8M. Regarding current trading prices, MSPRW is priced at $0.07, while INOV trades at $31.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPRW currently has a P/E ratio of N/A, whereas INOV's P/E ratio is 16.32. In terms of profitability, MSPRW's ROE is -3.08%, compared to INOV's ROE of +0.03%. Regarding short-term risk, MSPRW is less volatile compared to INOV. This indicates potentially lower risk in terms of short-term price fluctuations for MSPRW.Check INOV's competition here
MSPRW vs HCTI Comparison August 2025
MSPRW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPRW stands at 7K. In comparison, HCTI has a market cap of 12.7M. Regarding current trading prices, MSPRW is priced at $0.07, while HCTI trades at $4.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPRW currently has a P/E ratio of N/A, whereas HCTI's P/E ratio is N/A. In terms of profitability, MSPRW's ROE is -3.08%, compared to HCTI's ROE of -23.25%. Regarding short-term risk, MSPRW is less volatile compared to HCTI. This indicates potentially lower risk in terms of short-term price fluctuations for MSPRW.Check HCTI's competition here
MSPRW vs BFRG Comparison August 2025
MSPRW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPRW stands at 7K. In comparison, BFRG has a market cap of 12.2M. Regarding current trading prices, MSPRW is priced at $0.07, while BFRG trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPRW currently has a P/E ratio of N/A, whereas BFRG's P/E ratio is -1.62. In terms of profitability, MSPRW's ROE is -3.08%, compared to BFRG's ROE of -1.63%. Regarding short-term risk, MSPRW is less volatile compared to BFRG. This indicates potentially lower risk in terms of short-term price fluctuations for MSPRW.Check BFRG's competition here
MSPRW vs ETAO Comparison August 2025
MSPRW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPRW stands at 7K. In comparison, ETAO has a market cap of 9.8M. Regarding current trading prices, MSPRW is priced at $0.07, while ETAO trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPRW currently has a P/E ratio of N/A, whereas ETAO's P/E ratio is -0.01. In terms of profitability, MSPRW's ROE is -3.08%, compared to ETAO's ROE of -13.69%. Regarding short-term risk, MSPRW is less volatile compared to ETAO. This indicates potentially lower risk in terms of short-term price fluctuations for MSPRW.Check ETAO's competition here
MSPRW vs MSPR Comparison August 2025
MSPRW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPRW stands at 7K. In comparison, MSPR has a market cap of 8.4M. Regarding current trading prices, MSPRW is priced at $0.07, while MSPR trades at $0.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPRW currently has a P/E ratio of N/A, whereas MSPR's P/E ratio is N/A. In terms of profitability, MSPRW's ROE is -3.08%, compared to MSPR's ROE of -3.08%. Regarding short-term risk, MSPRW is less volatile compared to MSPR. This indicates potentially lower risk in terms of short-term price fluctuations for MSPRW.Check MSPR's competition here
MSPRW vs HLTH Comparison August 2025
MSPRW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPRW stands at 7K. In comparison, HLTH has a market cap of 6.9M. Regarding current trading prices, MSPRW is priced at $0.07, while HLTH trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPRW currently has a P/E ratio of N/A, whereas HLTH's P/E ratio is -0.02. In terms of profitability, MSPRW's ROE is -3.08%, compared to HLTH's ROE of -0.88%. Regarding short-term risk, MSPRW is less volatile compared to HLTH. This indicates potentially lower risk in terms of short-term price fluctuations for MSPRW.Check HLTH's competition here
MSPRW vs BFRGW Comparison August 2025
MSPRW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPRW stands at 7K. In comparison, BFRGW has a market cap of 5.5M. Regarding current trading prices, MSPRW is priced at $0.07, while BFRGW trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPRW currently has a P/E ratio of N/A, whereas BFRGW's P/E ratio is N/A. In terms of profitability, MSPRW's ROE is -3.08%, compared to BFRGW's ROE of -1.63%. Regarding short-term risk, MSPRW is less volatile compared to BFRGW. This indicates potentially lower risk in terms of short-term price fluctuations for MSPRW.Check BFRGW's competition here
MSPRW vs UPH Comparison August 2025
MSPRW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPRW stands at 7K. In comparison, UPH has a market cap of 5.3M. Regarding current trading prices, MSPRW is priced at $0.07, while UPH trades at $0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPRW currently has a P/E ratio of N/A, whereas UPH's P/E ratio is -0.07. In terms of profitability, MSPRW's ROE is -3.08%, compared to UPH's ROE of -1.05%. Regarding short-term risk, MSPRW is less volatile compared to UPH. This indicates potentially lower risk in terms of short-term price fluctuations for MSPRW.Check UPH's competition here
MSPRW vs ZCMD Comparison August 2025
MSPRW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPRW stands at 7K. In comparison, ZCMD has a market cap of 5.3M. Regarding current trading prices, MSPRW is priced at $0.07, while ZCMD trades at $0.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPRW currently has a P/E ratio of N/A, whereas ZCMD's P/E ratio is -8.42. In terms of profitability, MSPRW's ROE is -3.08%, compared to ZCMD's ROE of -0.03%. Regarding short-term risk, MSPRW is less volatile compared to ZCMD. This indicates potentially lower risk in terms of short-term price fluctuations for MSPRW.Check ZCMD's competition here
MSPRW vs FOXO Comparison August 2025
MSPRW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPRW stands at 7K. In comparison, FOXO has a market cap of 4.7M. Regarding current trading prices, MSPRW is priced at $0.07, while FOXO trades at $0.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPRW currently has a P/E ratio of N/A, whereas FOXO's P/E ratio is -0.01. In terms of profitability, MSPRW's ROE is -3.08%, compared to FOXO's ROE of -0.01%. Regarding short-term risk, MSPRW is less volatile compared to FOXO. This indicates potentially lower risk in terms of short-term price fluctuations for MSPRW.Check FOXO's competition here
MSPRW vs PEARW Comparison August 2025
MSPRW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPRW stands at 7K. In comparison, PEARW has a market cap of 4.1M. Regarding current trading prices, MSPRW is priced at $0.07, while PEARW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPRW currently has a P/E ratio of N/A, whereas PEARW's P/E ratio is -0.00. In terms of profitability, MSPRW's ROE is -3.08%, compared to PEARW's ROE of -0.39%. Regarding short-term risk, MSPRW is less volatile compared to PEARW. This indicates potentially lower risk in terms of short-term price fluctuations for MSPRW.Check PEARW's competition here
MSPRW vs PEAR Comparison August 2025
MSPRW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPRW stands at 7K. In comparison, PEAR has a market cap of 4.1M. Regarding current trading prices, MSPRW is priced at $0.07, while PEAR trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPRW currently has a P/E ratio of N/A, whereas PEAR's P/E ratio is -0.08. In terms of profitability, MSPRW's ROE is -3.08%, compared to PEAR's ROE of -0.39%. Regarding short-term risk, MSPRW is less volatile compared to PEAR. This indicates potentially lower risk in terms of short-term price fluctuations for MSPRW.Check PEAR's competition here
MSPRW vs ACON Comparison August 2025
MSPRW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPRW stands at 7K. In comparison, ACON has a market cap of 4.1M. Regarding current trading prices, MSPRW is priced at $0.07, while ACON trades at $7.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPRW currently has a P/E ratio of N/A, whereas ACON's P/E ratio is -0.61. In terms of profitability, MSPRW's ROE is -3.08%, compared to ACON's ROE of -1.27%. Regarding short-term risk, MSPRW is less volatile compared to ACON. This indicates potentially lower risk in terms of short-term price fluctuations for MSPRW.Check ACON's competition here
MSPRW vs EUDAW Comparison August 2025
MSPRW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPRW stands at 7K. In comparison, EUDAW has a market cap of 3.4M. Regarding current trading prices, MSPRW is priced at $0.07, while EUDAW trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPRW currently has a P/E ratio of N/A, whereas EUDAW's P/E ratio is N/A. In terms of profitability, MSPRW's ROE is -3.08%, compared to EUDAW's ROE of +3.05%. Regarding short-term risk, MSPRW is less volatile compared to EUDAW. This indicates potentially lower risk in terms of short-term price fluctuations for MSPRW.Check EUDAW's competition here
MSPRW vs WGSWW Comparison August 2025
MSPRW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPRW stands at 7K. In comparison, WGSWW has a market cap of 2.6M. Regarding current trading prices, MSPRW is priced at $0.07, while WGSWW trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPRW currently has a P/E ratio of N/A, whereas WGSWW's P/E ratio is N/A. In terms of profitability, MSPRW's ROE is -3.08%, compared to WGSWW's ROE of +0.01%. Regarding short-term risk, MSPRW is less volatile compared to WGSWW. This indicates potentially lower risk in terms of short-term price fluctuations for MSPRW.Check WGSWW's competition here
MSPRW vs OTRK Comparison August 2025
MSPRW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPRW stands at 7K. In comparison, OTRK has a market cap of 2.2M. Regarding current trading prices, MSPRW is priced at $0.07, while OTRK trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPRW currently has a P/E ratio of N/A, whereas OTRK's P/E ratio is -0.02. In terms of profitability, MSPRW's ROE is -3.08%, compared to OTRK's ROE of -2.70%. Regarding short-term risk, MSPRW is less volatile compared to OTRK. This indicates potentially lower risk in terms of short-term price fluctuations for MSPRW.Check OTRK's competition here
MSPRW vs CMAX Comparison August 2025
MSPRW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPRW stands at 7K. In comparison, CMAX has a market cap of 1.6M. Regarding current trading prices, MSPRW is priced at $0.07, while CMAX trades at $0.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPRW currently has a P/E ratio of N/A, whereas CMAX's P/E ratio is -0.00. In terms of profitability, MSPRW's ROE is -3.08%, compared to CMAX's ROE of +30.94%. Regarding short-term risk, MSPRW is less volatile compared to CMAX. This indicates potentially lower risk in terms of short-term price fluctuations for MSPRW.Check CMAX's competition here
MSPRW vs LIFWZ Comparison August 2025
MSPRW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPRW stands at 7K. In comparison, LIFWZ has a market cap of 1.3M. Regarding current trading prices, MSPRW is priced at $0.07, while LIFWZ trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPRW currently has a P/E ratio of N/A, whereas LIFWZ's P/E ratio is N/A. In terms of profitability, MSPRW's ROE is -3.08%, compared to LIFWZ's ROE of -3.08%. Regarding short-term risk, MSPRW and LIFWZ have similar daily volatility (0.00).Check LIFWZ's competition here
MSPRW vs WORX Comparison August 2025
MSPRW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPRW stands at 7K. In comparison, WORX has a market cap of 1.2M. Regarding current trading prices, MSPRW is priced at $0.07, while WORX trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPRW currently has a P/E ratio of N/A, whereas WORX's P/E ratio is -0.37. In terms of profitability, MSPRW's ROE is -3.08%, compared to WORX's ROE of -0.32%. Regarding short-term risk, MSPRW is less volatile compared to WORX. This indicates potentially lower risk in terms of short-term price fluctuations for MSPRW.Check WORX's competition here
MSPRW vs ICCT Comparison August 2025
MSPRW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPRW stands at 7K. In comparison, ICCT has a market cap of 182.9K. Regarding current trading prices, MSPRW is priced at $0.07, while ICCT trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPRW currently has a P/E ratio of N/A, whereas ICCT's P/E ratio is N/A. In terms of profitability, MSPRW's ROE is -3.08%, compared to ICCT's ROE of +20.01%. Regarding short-term risk, MSPRW is less volatile compared to ICCT. This indicates potentially lower risk in terms of short-term price fluctuations for MSPRW.Check ICCT's competition here
MSPRW vs KERN Comparison August 2025
MSPRW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPRW stands at 7K. In comparison, KERN has a market cap of 162.3K. Regarding current trading prices, MSPRW is priced at $0.07, while KERN trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPRW currently has a P/E ratio of N/A, whereas KERN's P/E ratio is -0.01. In terms of profitability, MSPRW's ROE is -3.08%, compared to KERN's ROE of -2.22%. Regarding short-term risk, MSPRW is less volatile compared to KERN. This indicates potentially lower risk in terms of short-term price fluctuations for MSPRW.Check KERN's competition here
MSPRW vs KERNW Comparison August 2025
MSPRW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPRW stands at 7K. In comparison, KERNW has a market cap of 162.3K. Regarding current trading prices, MSPRW is priced at $0.07, while KERNW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPRW currently has a P/E ratio of N/A, whereas KERNW's P/E ratio is -0.00. In terms of profitability, MSPRW's ROE is -3.08%, compared to KERNW's ROE of -2.22%. Regarding short-term risk, MSPRW is less volatile compared to KERNW. This indicates potentially lower risk in terms of short-term price fluctuations for MSPRW.Check KERNW's competition here
MSPRW vs OTRKP Comparison August 2025
MSPRW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPRW stands at 7K. In comparison, OTRKP has a market cap of 103.3K. Regarding current trading prices, MSPRW is priced at $0.07, while OTRKP trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPRW currently has a P/E ratio of N/A, whereas OTRKP's P/E ratio is -0.01. In terms of profitability, MSPRW's ROE is -3.08%, compared to OTRKP's ROE of -2.70%. Regarding short-term risk, MSPRW is less volatile compared to OTRKP. This indicates potentially lower risk in terms of short-term price fluctuations for MSPRW.Check OTRKP's competition here
MSPRW vs MSPRZ Comparison August 2025
MSPRW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPRW stands at 7K. In comparison, MSPRZ has a market cap of 71.1K. Regarding current trading prices, MSPRW is priced at $0.07, while MSPRZ trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPRW currently has a P/E ratio of N/A, whereas MSPRZ's P/E ratio is N/A. In terms of profitability, MSPRW's ROE is -3.08%, compared to MSPRZ's ROE of -3.08%. Regarding short-term risk, MSPRW is less volatile compared to MSPRZ. This indicates potentially lower risk in terms of short-term price fluctuations for MSPRW.Check MSPRZ's competition here
MSPRW vs LIFWW Comparison August 2025
MSPRW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPRW stands at 7K. In comparison, LIFWW has a market cap of 60.1K. Regarding current trading prices, MSPRW is priced at $0.07, while LIFWW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPRW currently has a P/E ratio of N/A, whereas LIFWW's P/E ratio is N/A. In terms of profitability, MSPRW's ROE is -3.08%, compared to LIFWW's ROE of -3.08%. Regarding short-term risk, MSPRW and LIFWW have similar daily volatility (0.00).Check LIFWW's competition here
MSPRW vs CMAXW Comparison August 2025
MSPRW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPRW stands at 7K. In comparison, CMAXW has a market cap of 36.4K. Regarding current trading prices, MSPRW is priced at $0.07, while CMAXW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPRW currently has a P/E ratio of N/A, whereas CMAXW's P/E ratio is N/A. In terms of profitability, MSPRW's ROE is -3.08%, compared to CMAXW's ROE of +30.94%. Regarding short-term risk, MSPRW and CMAXW have similar daily volatility (0.00).Check CMAXW's competition here
MSPRW vs ACONW Comparison August 2025
MSPRW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPRW stands at 7K. In comparison, ACONW has a market cap of 15.3K. Regarding current trading prices, MSPRW is priced at $0.07, while ACONW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPRW currently has a P/E ratio of N/A, whereas ACONW's P/E ratio is N/A. In terms of profitability, MSPRW's ROE is -3.08%, compared to ACONW's ROE of -1.27%. Regarding short-term risk, MSPRW and ACONW have similar daily volatility (0.00).Check ACONW's competition here
MSPRW vs UTRS Comparison August 2025
MSPRW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPRW stands at 7K. In comparison, UTRS has a market cap of 888. Regarding current trading prices, MSPRW is priced at $0.07, while UTRS trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPRW currently has a P/E ratio of N/A, whereas UTRS's P/E ratio is N/A. In terms of profitability, MSPRW's ROE is -3.08%, compared to UTRS's ROE of -1.11%. Regarding short-term risk, MSPRW and UTRS have similar daily volatility (0.00).Check UTRS's competition here
MSPRW vs MTBCO Comparison August 2025
MSPRW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPRW stands at 7K. In comparison, MTBCO has a market cap of 0. Regarding current trading prices, MSPRW is priced at $0.07, while MTBCO trades at $25.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPRW currently has a P/E ratio of N/A, whereas MTBCO's P/E ratio is N/A. In terms of profitability, MSPRW's ROE is -3.08%, compared to MTBCO's ROE of +0.21%. Regarding short-term risk, MSPRW is less volatile compared to MTBCO. This indicates potentially lower risk in terms of short-term price fluctuations for MSPRW.Check MTBCO's competition here
MSPRW vs CERN Comparison August 2025
MSPRW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPRW stands at 7K. In comparison, CERN has a market cap of 0. Regarding current trading prices, MSPRW is priced at $0.07, while CERN trades at $94.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPRW currently has a P/E ratio of N/A, whereas CERN's P/E ratio is 55.84. In terms of profitability, MSPRW's ROE is -3.08%, compared to CERN's ROE of +0.14%. Regarding short-term risk, MSPRW is less volatile compared to CERN. This indicates potentially lower risk in terms of short-term price fluctuations for MSPRW.Check CERN's competition here
MSPRW vs CHNG Comparison August 2025
MSPRW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPRW stands at 7K. In comparison, CHNG has a market cap of 0. Regarding current trading prices, MSPRW is priced at $0.07, while CHNG trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPRW currently has a P/E ratio of N/A, whereas CHNG's P/E ratio is -152.72. In terms of profitability, MSPRW's ROE is -3.08%, compared to CHNG's ROE of -0.05%. Regarding short-term risk, MSPRW is less volatile compared to CHNG. This indicates potentially lower risk in terms of short-term price fluctuations for MSPRW.Check CHNG's competition here
MSPRW vs CHNGU Comparison August 2025
MSPRW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPRW stands at 7K. In comparison, CHNGU has a market cap of 0. Regarding current trading prices, MSPRW is priced at $0.07, while CHNGU trades at $73.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPRW currently has a P/E ratio of N/A, whereas CHNGU's P/E ratio is N/A. In terms of profitability, MSPRW's ROE is -3.08%, compared to CHNGU's ROE of -0.05%. Regarding short-term risk, MSPRW is less volatile compared to CHNGU. This indicates potentially lower risk in terms of short-term price fluctuations for MSPRW.Check CHNGU's competition here